One-carbon metabolism in psychiatric illness

Nutrition Research Reviews

Volumn 19, Issue 1, 2006, Pages 117-136

  Sugden, C ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Autism; Epigenetics; Methylation; One carbon metabolism; Psychiatric illness; S adenosylmethionine

Indexed keywords

BETAINE HOMOCYSTEINE METHYLTRANSFERASE; COBALAMIN; FOLIC ACID; GLUTATHIONE; GLYCINE HYDROXYMETHYLTRANSFERASE; METHIONINE; METHIONINE ADENOSYLTRANSFERASE; METHIONINE SYNTHASE; METHYLENETETRAHYDROFOLIC ACID; METHYLTRANSFERASE; NICOTINIC ACID; REELIN; S ADENOSYLMETHIONINE;

ADAPTATION; AUTISM; BEHAVIOR; BIPOLAR DISORDER; COGNITION; COST BENEFIT ANALYSIS; DEPRESSION; DIET SUPPLEMENTATION; DISEASE MARKER; ECONOMIC ASPECT; ENZYME ACTIVITY; ENZYME REGULATION; EPIGENETICS; FOLATE METABOLISM; GENE EXPRESSION; HUMAN; LEARNING; MEMBRANE FLUIDITY; MEMORY; MENTAL DISEASE; METHYLATION; NUTRITIONAL SUPPORT; OXIDATIVE STRESS; PREGNANCY; PUBLIC HEALTH; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE; UNITED KINGDOM; VITAMIN DEFICIENCY;

ANIMALIA;

EID: 33746845341     PISSN: 09544224     EISSN: None     Source Type: Journal    
DOI: 10.1079/NRR2006119     Document Type: Review

References (143)

1. Abdolmaleky HM, Smith CL, Faraone SV, Shafa R, Stone W, Glatt SJ & Tsuang MT (2003) Methylomics in psychiatry: modulation of gene-environment interactions may be through DNA methylation. American Journal of Medical Genetics 127B, 51-59.
2. Ahokas A, Aito M & Turianen S (2000) Association between oestradiol and puerperal psychosis. Acta Psychiatrica Scandinavica 101, 167-169.
3. Alpert JE & Fava M (1997) Nutrition and depression: the role of folate. Nutrition Reviews 55, 145-149.
4. Andreoli VM & Maffei F (1975) Blood-levels of S-adenosyl-methionine in schizophrenia. Lancet 306, 922.
5. Anonymous (1991) Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 338, 131-137.
6. Antun FT, Burnett GB, Cooper AJ, Daly RJ, Smythies JR & Zealley AK (1971) The effects of L-methionine (without MAOI) in schizophrenia. Journal of Psychiatric Research 8, 63-71.
7. Applebaum J, Shimon H, Sela B-A, Belmaker RH & Levaine J (2004) Homocysteine levels in newly admitted schizophrenic patients. Journal of Psychiatric Research 38, 413-416.
8. Arinami T, Yamada N, Yamakawa-Kobayashi K, Hamaguchi H & Toru M (1997) Methylenetetrahydrofolate reductase variant and schizophrenia/depression. American Journal of Medical Genetics (Neuropsychiatric Genetics) 74, 526-528.
9. Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, Bennett C, Ranjekar PK & Mahadik SP (2003) Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenic patients. Biological Psychiatry 53, 56-64.
10. Bennett CN & Horrobin DF (2003) Impaired niacin flushing in schizophrenia: possible biological mechanisms. Schizophrenia Research 60, Suppl. 1, 98.
11. Bentall R (2003) Power to the patients. New Scientist, 40-43, 30 August 2003.
12. Bertolino A, Caforio G, Blasi G, De Candia M, Lattore V, Petruzzella V, Altamura M, Nappi G, Papa S, Callicott JH, et al. (2004) Interaction of COMT val 108/158 met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. American Journal of Psychiatry 161, 1798-1805.
13. Borroni B, Agosti C, Archetti S, Costanzi C, Bonomi S, Ghianda D, Lenzi GL, Caimi L, Di Luca M & Padovani A (2004) Catechol-O-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer disease. Neuroscience Letters 370, 127-129.
14. Botez MI, Young SN, Bachevalier J & Gautier S (1979) Folate deficiency and decreased 5-hydroxytryptamine synthesis in man. Nature 278, 182-183.
15. Bottiglieri T (2002) S-adenosyl-L-methionine (SAMe): from the bench to the bedside - molecular basis of a pleiotrophic molecule. American Journal of Clinical Nutrition 76, Suppl., 1151S-1157S.
16. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MWP & Reynolds EH (2000) Homocysteine, folate, methylation, and monoamine metabolism in depression. Journal of Neurology, Neurosurgery and Psychiatry 69, 228-232.
17. Brockington IF & Meakin CJ (1994) Clinical clues to the aetiology of puerperal psychosis. Progress in Neuropsychopharmacology and Biological Psychiatry 18, 417-429.
18. Carboni G, Tueting P, Tremolizzo I, Sugaya I, Davis J, Costa E & Guidotti A (2004) Enhanced dizocilpine efficacy in heterozygous reeler mice relates to GABA turnover downregulation. Neuropharmacology 46, 1070-1081.
19. Chagoya de Sanchez VC, Hernandez-Munoz R, Sanchez L, Vidrio S, Yanez L & Suarez J (1991) Twenty-four hour changes of S-adenosylmethionine, S-adenosylhomocysteine adenosine and their metabolising enzymes in rat liver; possible physiological significance in phospholipid methylation. International Journal of Biochemistry 23, 1439-1443.
20. Chen Y, Sharma RP, Costa RH, Costa E & Grayson DR (2002) On the epigenetic regulation of the human reelin. Nucleic Acids Research 30, 2930-2939.
21. Chiaie RD, Pancheri P & Scapicchio P (2002) Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition 76, Suppl., 1172S-1176S.
22. Christman JK, Sheikhnejad G, Dizik M, Abileah S & Wainfan E (1993) Reversibility of changes in nucleic acid methylation and gene expression induced in rat liver by severe methyl deficiency. Carcinogenesis 14, 551-557.
23. Clarke S & Banfield K (2001) S-adenosylmethionine-dependent methyltransferases. In Homocysteine in Health and Disease, pp. 63-78 [R Carmel and DW Jacobsen, editors]. Cambridge, UK: Cambridge University Press.
24. Cohen M, Dembling B & Schorling J (2002) The association between schizophrenia and cancer: a population-based mortality study. Schizophrenia Research 57, 139-146.
25. Cook RJ (2001) Folate metabolism. In Homocysteine in Health and Disease, pp. 113-134 [R Carmel and DW Jacobsen, editors]. Cambridge, UK: Cambridge University Press.
26. Cooney CA, Dave AA & Wolff GL (2002) Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. Journal of Nutrition 132, 2393S-2400S.
27. da Costa K-A, Badea M, Fischer LM & Zeisel SH (2004) Elevated serum creatine phosphokinase in choline-deficient humans: mechanistic studies in C2C12 mouse myoblasts. American Journal of Clinical Nutrition 80, 163-170.
28. Davis SR, Stacpoole PW, Williamson J, Kick LS, Quinlivan EP, Coats BS, Shane B, Bailey LB & Gregory JF III (2004) Tracer-derived total and folate-dependent homocysteine remethylation and synthesis rates in humans indicate that serine is the main one-carbon donor. American Journal of Physiology 286, E272-E279.
29. DeLong CJ, Hicks AM & Cui Z (2002) Disruption of choline methyl group donation for phosphatidylethanolamine methylation in hepatocarcinoma cells. Journal of Biological Chemistry 19, 17217-17225.
30. DeLong CJ, Shen Y-J, Thomas MJ & Ciu Z (1999) Molecular distinction of phosphatidylcholine synthesis between the CDP-choline pathway and phosphatidylethanolamine methylation pathway. Journal of Biological Chemistry 274, 29683-29688.
31. Deth RC, DuRand CJ, Sharma A & Liu D (1996) Lymphocyte phospholipid methylation is altered in schizophrenia. Biological Psychiatry 39, 504.
32. Detich N, Bovenzi V & Szyf M (2003) Valproate induces replication-independent active DNA demethylation. Journal of Biological Chemistry 278, 27586-27592.
33. Ding D & Greenberg ML (2003) Lithium and valproate decrease the membrane phosphatidylinositol/phosphatidylcholine ratio. Molecular Microbiology 47, 373-381.
34. Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P & Cuenod M (2000) Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. European Journal of Neuroscience 12, 3721-3728.
35. Doraiswamy M, Martin W, Metz A & Deveaugh-Geiss J (1995) Psychosis in Parkinson's disease: diagnosis and treatment. Progress in Neuro- Psychopharmacology and Biological Psychiatry 19, 835-846.
36. Drouva SV, Rerat E, Leblanc P, Laplante E & Kordon C (1987) Variations of phospholipid methyltransferase(s) activity in the rat pituitary: estrous cycle and sex differences. Endocrinology 121, 569-574.
37. Durand C, Mary S, Brazo P & Dollfus S (2003) Psychiatric manifestations of vitamin B12 deficiency: a case report. Encephale 29, 560-565.
38. Durand P, Prost M & Blache D (1995) Pro-thrombic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis 121, 231-243.
39. Ende G, Braus DF, Walter S, Weber-Fahr W & Henn FA (2000) The hippocampus in patients treated with electroconvulsive therapy. Archives of General Psychiatry 57, 937-943.
40. Fan J-B, Zhang C-S, Gu N-F, Li X-W, Sun W-W, Wany H-Y, Geny G-Y, St Clair D & Hee L (2005) Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. Biological Psychiatry 57, 139-144.
41. Fatemi SH, Stary JM, Earle JA, Araghi-Nikman M & Eagan E (2005) GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and reelin proteins in cerebellum. Schizophrenia Research 72, 109-122.
42. Fatemi SH, Stary JM, Halt AR & Realmuto GR (2001) Dysregulation of reelin and Bcl-2 proteins in autistic cerebellum. Journal of Autism and Developmental Disorders 31, 529-535.
43. Finnell RH, Spiegelstein O, Wlodarczyk B, Triplett A, Pogribny IP, Melnyk S & James JS (2002) DNA methylation in FolBP1 knockout mice supplemented with folic acid during gestation. Journal of Nutrition 132, 2457S-2461S.
44. Fournier I, Ploye F, Cottet-Emard J-M, Brun J & Claustrat B (2002) Folate deficiency alters melatonin secretion in rats. Journal of Nutrition 132, 2781-2784.
45. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, Heine-Suner D, Cigudosa JC, Urioste M, Benitez J, et al. (2005) Epigenetic differences arise during the lifetime of monozygotic twins. Proceedings of the National Academy of Sciences USA 102, 10604-10609.
46. Glatt SJ, Faraone SV & Tsuang MT (2003) Association between a functional catechol-O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. American Journal of Psychiatry 160, 469-476.
47. Glen ACA, MacDonald DJ & Boyle RM (2003a) Cytosolic phospholipase A2 (IVAPLA2) in red cells in schizophrenia and other psychiatric disorders. In Phospholipid Spectrum Disorders in Psychiatry, pp. 183-192 [M Peet, I Glen and DF Horrobin, editors]. Carnforth, Lanes, UK: Marius Press.
48. Glen I, McKenzie I, Obajimi K, Dodd GH, Ward PE & Ross BM (2003b) Markers of oxidative damage in exhalant and their use in schizophrenia and other disorders. In Phospholipid Spectrum Disorders in Psychiatry, pp. 357-364 [M Peet, I Glen and DF Horrobin, editors]. Carnforth, Lanes, UK: Marius Press.
49. Gluckman P & Hanson M (2005) The Fetal Matrix. Evolution, Development and Disease. Cambridge, UK: Cambridge University Press.
50. Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, Chanarin I & Reynolds EH (1990) Enhancement of recovery from psychiatric illness by methylfolate. Lancet 336, 392-395.
51. Goff DC, Bottiglieri T, Arning E, Shih V, Freundenreich O, Evins AE, Henderson DC, Baer L & Coyle J (2004) Folate, homocysteine and negative symptoms in schizophrenia. American Journal of Psychiatry 161, 1705-1708.
52. Grima G, Benz B, Parpura V, Cuenod M & Do KQ (2003) Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophrenia Research 62, 213-224.
53. Grinshpoon A, Barchana M, Ponizovsky A, Lipshitz I, Nahon D, Tal O, Weizman A & Levav I (2005) Cancer in schizophrenia: is the risk higher or lower? Schizophrenia Research 73, 333-341.
54. 67) expression in schizophrenia and bipolar disorder. Archives of General Psychiatry 57, 1061-1069.
55. Gultepe M, Ozcan O, Avsar K, Cetin M, Ozdemir AS & Gok M (2003) Urine methylmalonic acid measurements for the assessment of cobalamin deficiency related to neuropsychiatric disorders. Clinical Biochemistry 36, 275-282.
56. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G & Lichtenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry 56, 29-36.
57. Hermesh H, Manor I, Shiloh R, Weizman R & Munitz H (2001) Absence of myoglobinuria in acute psychotic patients with marked elevation in serum creatine phosphokinase level. European Neuropsychopharmacology 11, 111-115.
58. Hirata F & Axelrod J (1980) Phospholipid methylation and biological signal transmission. Science 209, 1082-1090.
59. Hoffer A, Osmond H & Smythies JR (1954) Schizophrenia: a new approach. Part II. Journal of Mental Science 100, 29-45.
60. Hook EB & Czeizel AE (1997) Can terathanasia explain the protective effect of folic-acid supplementation on birth defects? Lancet 350, 513-515.
61. Horrobin DF (1999) The phospholipid concept of psychiatric disorders and its relationship to the neurodevelopmental concept of schizophrenia. In Phospholipid Spectrum Disorder in Psychiatry, pp. 3-20 [M Peet, I Glen and DF Horrobin, editors]. Carnforth, Lanes, UK: Marius Press.
62. Hunter R, Barnes J, Oakeley HF & Matthews DM (1970) Toxicity of folic acid given in pharmacological doses to healthy volunteers. Lancet i, 61-63.
63. Hustad S, Ueland PM, Vollset SE, Zhang Y, Bjorke-Monsen AL & Schneede J (2000) Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clinical Chemistry 46, 1065-1071.
64. Impagnatiello F, Guidotti A, Pesold C, Dwivedi Y, Caruncho H, Pisu MG, Uzunov DP, Smalheiser NR, Davis JM, Pandey GN, et al. (1998) A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proceedings of the National Academy of Sciences USA 95, 15718-15723.
65. Ingrosso D, Cimmino A, Perna AF, Masella L, De Santo NG, De Bonis ML, Vacca M, D'Esposito M, D'Urso M, Galletti P, et al. (2003) Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 361, 1693-1699.
66. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DE & Neubrander JA (2004) Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. American Journal of Clinical Nutrition 80, 1611-1617.
67. Joober R, Benkelfat C, Lal S, Bloom D, Labelle A, Lalonde P, Turecki G, Rozen R & Rouleau GA (2000) Association between the methylenetetrahydrofolate reductase 677C-T missense mutation and schizophrenia. Molecular Psychiatry 5, 323-326.
68. Khan M, Evans D, Gunna V, Scheffer RE, Parikh VV & Mahadik SP (2002) Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophrenia Research 58, 1-10.
69. Kim YI (2000) Methylenetetrahydrofolate reductase polymorphisms, folate, and cancer risk: a paradigm of gene-nutrient interactions in carcinogenesis. Nutrition Reviews 58, 205-209.
70. Kingsbury SJ & Garver DL (1998) Lithium and psychosis revisited. Progress in Neuro-psychopharmacology and Biological Psychiatry 22, 249-263.
71. Levi RN & Waxman S (1975) Schizophrenia, epilepsy, cancer, methionine, and folate metabolism. Pathogenesis of schizophrenia. Lancet ii, 11-13.
72. Levine J, Agam G, Sela BA, Garver DL, Torrey EF & Belmaker RH (2005) CSF homocysteine is not elevated in schizophrenia. Journal of Neural Transmission 112, 297-302.
73. Levine J, Stahl Z, Sela BA, Gavendo S, Ruderman V & Belmaker RH (2002) Elevated homocysteine levels in young male patients with schizophrenia. American Journal of Psychiatry 159, 1790-1792.
74. Lewis SJ, Zammit S, Gunnell D & Smith GD (2005) A meta-analysis of the MTHFR C677T polymorphism and schizophrenia risk. American Journal of Medical Genetics (Neuropsychiatric Genetics) 135B, 2-4.
75. Lindenbaum J, Healton EB & Savage DG (1988) Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. New England Journal of Medicine 318, 1720-1728.
76. Lipton SA, Kim W-K, Choi Y-B, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR & Stamler JS (1997) Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proceedings of the National Academy of Sciences USA 94, 5923-5928.
77. McGrath M, Kawachi I, Ascherio A, Colditz GA, Hunter DJ & De Vivo I (2004) Association between catechol-O-methyltransferase and phobic anxiety. American Journal of Psychiatry 161, 1703-1705.
78. Maclean R, Ward PE, Glen I, Roberts SJ & Ross BM (2003) On the relationship between methylnicotinate-induced skin-flush and fatty acids levels in acute psychosis. Progress in Neuropsychopharmacology and Biological Psychiatry 27, 927-933.
79. McNulty H, McKinley M, Wilson B, McPartlin J, Strain JJ, Weir DG & Scott JM (2002) Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirements. American Journal of Clinical Nutrition 76, 436-441.
80. Manor I, Hermesh H, Valevski A, Benjamin Y, Munitz H & Weizman A (1998) Recurrence pattern of serum creatine phosphokinase levels in repeated acute psychosis. Biological Psychiatry 43, 288-292.
81. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG & Wolf PA (2003) Effect of 1-dopa on plasma homocysteine in PD patients. Neurology 60, 1125-1129.
82. Mischoulon D & Fava M (2002) Role of S-adenosyl-methionine in the treatment of depression: a review of the evidence. American Journal of Clinical Nutrition 76, Suppl., 1158S-1161S.
83. Molloy AM & Weir DG (2001) Homocysteine and the nervous system. In Homocysteine in Health and Disease, pp. 183-198 [R Carmel and DW Jacobsen, editors]. Cambridge, UK: Cambridge University Press.
84. Muller T, Renger K & Kuhn W (2004) Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Archives of Neurology 61, 657-660.
85. Munoz-Moran E, Dieguez-Lucena JL, Fernandez-Arcas N, Peran-Mesa S & Reyes-Engel A (1998) Genetic selection and folate intake during pregnancy. Lancet 352, 1120-1121.
86. Muntjewerff J-W, van der Put N, Eskes T, Ellenbroek B, Steegers E, Blom H & Zitman F (2003) Homocysteine metabolism and B-vitamins in schizophrenic patients: low plasma folate as a possible independent risk factor for schizophrenia. Psychiatry Research 121, 1-9.
87. Na C & Lee YS (2004) Serum homocysteine, folate level and MTHFR 677, 1298 gene polymorphism in schizophrenia. European Neuropsychopharmacology 14, Suppl. 3, S232-S233.
88. Noh JS, Sharma RP, Veldic M, Salvacion AA, Jia X, Chen Y, Costa E, Guidotti A & Grayson DR (2004) DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures. Proceedings of the National Academy of Sciences USA 102, 1749-1754.
89. Noga AA, Stead LM, Zhao Y, Brosnan ME, Brosnan JT & Vance DE (2003) Plasma homocysteine is regulated by phospholipid methylation. Journal of Biological Chemistry 278, 5952-5955.
90. Noga AA & Vance DE (2003) A gender-specific role for phosphatidylethanolamine-N-methyltransferase-derived phosphatidylcholine in the regulation of plasma high density and very low density lipoproteins in mice. Journal of Biological Chemistry 278, 21851-21859.
91. Olney JW, Newcomer JW & Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research 33, 523-533.
92. Oltean S & Banerjee R (2003) Nutritional modulation of gene expression and homocysteine utilisation by vitamin B12. Journal of Biological Chemistry 278, 20778-20784.
93. Osher Y, Sela B-A, Levine J & Belmaker RH (2004) Elevated homocysteine levels in euthymic bipolar disorder patients showing functional deterioration. Bipolar Disorders 6, 82.
94. Peet M & Bennett CN (1999) Relationship between brain lipids, depression and suicide. In Phospholipid Spectrum Disorder in Psychiatry, pp. 403-408 [M Peet, I Glen and DF Horrobin, editors]. Carnforth, Lancs, UK: Marius Press.
95. Peet M, Brind J, Ramchand CN, Shah S & Vankar GK (2000) Two double-blind placebo-controlled pilot studies of eicosapentanoic acid in the treatment of schizophrenia. Schizophrenia Research 49, 243-251.
96. Persico AM, D'Agruma L, Maiorano N, Totaro A, Militerni R, Bravaccio C, Wassink TH, Schneider C, Melmed R, Trillo S, et al. (2001) Reelin gene alleles and haplotypes as a factor predisposing to autistic disorder. Molecular Psychiatry 6, 150-159.
97. Petronis A, Gottesman II, Kan P, Kennedy JL, Basile VS, Paterson AD & Popendikyte V (2003) Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? Schizophrenia Bulletin 29, 169-178.
98. Petry CJ, Ozanne SE & Hales CN (2001) Programming of intermediary metabolism. Molecular and Cellular Endocrinology 185, 81-91.
99. Quinlivan EP & Gregory JF III (2003) Effect of food fortification on folic acid intake in the United States. American Journal of Clinical Nutrition 77, 221-225.
100. Rees WD, Hay SM, Brown DS, Antipatis C & Palmer RM (2000) Maternal protein deficiency causes hypermethylation of DNA in the livers of rat fetuses. Journal of Nutrition 130, 1821-1826.
101. Regland B, Abrahamsson L, Blennow K, Grebfeldt B & Gottfries CG (2004) CSF-methionine is elevated in psychotic patients. Journal of Neural Transmission 111, 631-640.
102. Reichelt KL, Hole K, Hamberger A, Saelid G, Edminson PD, Braestrup CB, Lingjaerde O, Ledaal P & Orbeck H (1981) Biologically active peptide-containing fractions in schizophrenia and childhood autism. Advances in Biochemical Psychopharmacology 28, 627-643.
103. Reynolds EH (2002) Benefits and risks of folic acid to the nervous system. Journal of Neurology, Neurosurgery and Psychiatry 72, 567-571.
104. Rogers JD, Sanchez-Saffron A, Frol AB & Diaz-Arrastia R (2003) Elevated plasma homocysteine in patients treated with levodopa: association with vascular disease. Archives of Neurology 60, 59-64.
105. Rosa A, Peralta V, Cuesta MJ, Zarzuela A, Serrano F, Martinez-Larrea A & Fananas L (2004) New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. American Journal of Psychiatry 161, 1110-1112.
106. Ross BM, Hudson C, Erlich J, Warsh JJ & Kish SJ (1997) Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of calcium-independent phospholipase A2. Archives of General Psychiatry 54, 487-494.
107. Rowling MJ, McMullen MH, Chipman DC & Schalinske KL (2002) Hepatic glycine N-methyltransferase is up-regulated by excess dietary methionine in rats. Journal of Nutrition 132, 2545-2550.
108. Sargent T III, Kusubov N, Taylor SE & Budinger TF (1992) Tracer kinetic evidence for abnormal methyl metabolism in schizophrenia. Biological Psychiatry 32, 1078-1090.
109. Sarmiento IA, Stoll AL & Cohen B (1999) The role of essential lipids in the management of bipolar disorder. In Phospholipid Spectrum Disorder in Psychiatry, pp. 457-462 [M Peet, I Glen and DF Horrobin, editors]. Carnforth, Lancs, UK: Marius Press.
110. Sartorius A, Neumann-Haefelin C, Vollmayr B, Hoehn M & Henn FA (2003) Choline rise in the rat hippocampus induced by electroconvulsive shock treatment. Biological Psychiatry 53, 620-623.
111. Sazci A, Ergul E, Guzelhan Y, Kaya G & Kara I (2003) Methylenetetrahydrofolate reductase gene polymorphisms in patients with schizophrenia. Molecular Brain Research 117, 104-107.
112. Shumeiko O, Levine J, Sela BA & Belmaker RH (2003) Homocysteine reducing strategies in chronic schizophrenic patients with hyperhomocysteinemia. European Journal of Neuropsychopharmacology 13, Suppl. 4, S280-S281.
113. Singh U, Yokota K, Gupta C & Shinozuka H (1990) Choline deficiency activates phospholipases A2 and C in rat liver without affecting the activity of protein kinase C. Journal of Nutritional Biochemistry 1, 434-439.
114. Slack A, Cervoni N, Pinard M & Schizophrenicyf M (1999) Feedback regulation of DNA methyltransferase gene expression by methylation. European Journal of Biochemistry 264, 191-199.
115. Stahl Z, Belmaker RH, Friger M & Levine J (2005) Nutritional and life style determinants of plasma homocysteine in schizophrenic patients. European Neuropsychopharmacology 15, 291-295.
116. Stead LM, Jacobs RL, Brosnan ME & Brosnan JT (2004) Methylation demand and homocysteine metabolism. Advances in Enzyme Regulation 44, 321-333.
117. Susser E, Brown AS, Klonowski E, Allen RH & Lindenbaum J (1998) Schizophrenia and impaired homocysteine metabolism: a possible association. Biological Psychiatry 44, 141-143.
118. Tiemeier H, Ruud van Tuijl H, Hofman A, Meijer J, Kilian AJ & Breteler MMB (2002) Vitamin B12, folate, and homocysteine in depression: The Rotterdam Study. American Journal of Psychiatry 159, 2099-2101.
119. Tolbert LC, Monti JA, Walter-Ryan W, Alarcon RD, Bahar B, Keriotis JT, Allison JG, Cates A, Antun F & Smythies JR (1988) Clinical correlations of one-carbon metabolism abnormalities. Progress in Neuropsychopharmacology and Biological Psychiatry 12, 491-502.
120. Tolmunen T, Hintikka J, Ruusunen A, Voutilainen S, Tanskanen A, Valkonen VP, Viinamaki H, Kaplan GA & Salonen JT (2004) Dietary folate and the risk of depression in Finnish middle-aged men. A prospective follow-up study. Psychotherapy and Psychosomatics 73, 334-339.
121. Tolmunen T, Voutilainen S, Hintikka J, Rissanen T, Tanskanen A, Viinamaki H, Kaplan GA & Salonen JT (2003) Dietary folate and depressive symptoms are associated in middle-aged Finnish men. Journal of Nutrition 133, 3233-3236.
122. Tremolizzo L, Carboni G, Ruzicka WB, Mitchell CP, Sugaya I, Tueting P, Sharma R, Grayson DR, Costa E & Guidotti A (2002) An epigenetic mouse model for molecular and behavioural neuropathologies related to schizophrenia vulnerability. Proceedings of the National Academy of Sciences USA 99, 17095-17100.
123. Tremolizzo L, Doueiri M-S, Dong E, Grayson DR, Davis J, Pinna G, Tueting P, Rodriguez-Menendez V, Costa E & Guidotti A (2005) Valproate corrects the schizophrenia-like epigenetic behavioural modifications induced by methionine in mice. Biological Psychiatry 57, 500-509.
124. Tsai G, Lane H-Y, Yang P, Chong M-Y & Lange N (2004) Glycine transporter 1 inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 55, 452-456.
125. Tsai G, Tang P, Chung L-C, Lange N & Coyle JT (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 44, 1081-1089.
126. Tuominen HJ, Tiihonen J & Wahlbeck K (2005) Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 72, 225-234.
127. Ueland PM, Hustad S, Schneede J, Refsum H & Vollset SE (2001) Biological and clinical implications of the MTHFR C677T polymorphism. Trends in Pharmacological Sciences 22, 195-201.
128. Vance DE, Walkey CJ & Cui Z (1997) Phosphatidylethanolamine N-methyltransferase from liver. Biochimica et Biophysica Acta 1348, 142-150.
129. Veldic M, Caruncho HJ, Liu WS, Davis J, Satta R, Grayson DR, Guidotti A & Costa E (2004a) DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains. Proceedings of the National Academy of Sciences USA 101, 348-353.
130. Veldic M, Guidotti A, Maloku E, Davis JM & Costa E (2004b) In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proceedings of the National Academy of Sciences USA 102, 2152-2157.
131. Virgos C, Martorell L, Simo JM, Valero J, Figureuera L, Joven J, Labad A & Vilella E (1999) Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia. Neuroreport 10, 2035-2038.
132. Waterland RA & Jirtle RL (2003) Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Molecular and Cellular Biology 23, 5293-5300.
133. Watkins SM, Zhu X & Zeisel SH (2003) Phosphatidylethanolamine-N- methyltransferase activity and dietary choline regulate liver-plasma lipid flux and essential fatty acid metabolism in mice. Journal of Nutrition 133, 3386-3391.
134. Waziri R, Baruah S & Sherman AD (1992) Abnormal serine-glycine metabolism in the brains of schizophrenics. Schizophrenia Research 8, 233-243.
135. Waziri R & Mott J (1986) Drug effects on serine metabolism in psychiatric patients. Psychiatry Research 18, 119-126.
136. Weaver ICG, Champagne FA, Brown SE, Dymov S, Sharma S, Meaney MJ & Szyf M (2005) Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. Journal of Neuroscience 25, 11045-11054.
137. Weickert TW, Goldberg TE, Mishara A, Apud JA, Kolachana BS, Egan MF & Weinberger DR (2004) Catechol-O-methyltransferase Val108/158Met genotype predicts working memory response to antipsychotic medications. Biological Psychiatry 56, 677-682.
138. Weir DG & Molloy AM (2000) Microvascular disease and dementia in the elderly: are they related to hyperhomocysteinemia? American Journal of Clinical Nutrition 71, 859-860.
139. Weir DG & Scott JM (1995) The biochemical basis of the neuropathy in cobalamin deficiency. Bailliere's Clinical Haematology 8, 479-497.
140. Weisberg I, Tran P, Christensen B, Sibani S & Rozen R (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Molecular Genetics and Metabolism 64, 169-172.
141. Wyatt RJ, Termini BA & Davis J (1971) Biochemical and sleep studies of schizophrenia: a review of the literature - 1960-1970. Schizophrenia Bulletin 4, 10-44.
142. Zeisel SH, Mar M-H, Howe JC & Holden JM (2003) Concentrations of choline-containing compounds and betaine in common foods. Journal of Nutrition 133, 1302-1307.
143. Zhao R, Chen Y, Tan W, Waly M, Sharma A, Stover P, Rosowsky A, Malewicz B & Deth RC (2001) Relationship between dopamine-stimulated phospholipid methylation and the single-carbon folate pathway. Journal of Neurochemistry 78, 788-796.